Some types of PD-1 and PD-L1 inhibitors are available as subcutaneous injections that a cancer care professional injects into fat under the skin. These subcutaneous medications include ...

Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug ...

The subcutaneous formulation of daratumumab makes treatment a faster and more tolerable process for patients with multiple ...

Subcutaneous injections of Darbe have been used to effectively treat anemia of prematurity and boost red blood cell ...

VYVGART® is first-and-only targeted IgG Fc-antibody fragment for CIDPFirst novel mechanism of action for CIDP treatment in more than 30 yearsCHMP positive opinion based on ADHERE data, the largest ...

Using the latest data and perspectives, an international expert panel releases updated recommendations for optimal insulin ...

Hooven, Chairman and CEO of Enable Injections. “Our enFuse platform is uniquely positioned to address challenges in developing large-volume subcutaneous oncology drugs. This wearable delivery ...

The injection takes just 3-5 min to administer ... This randomised, open-label phase 3 clinical trial compared subcutaneous and IV nivolumab in patients with previously treated advanced or ...